Sign In

Hans-Peter Gerber

Chief Scientific Officer at 3T Biosciences

Hans-Peter Gerber boasts over two decades of research and development experience in the Biotech and Big Pharma sectors, specializing in biotherapeutics and novel therapeutic platforms focused on oncology.

His expertise lies in oncology and immune-oncology R&D, covering areas like target identification, therapeutic modalities, lead compounds, companion diagnostics, translational support for early clinical development, and regulatory filings.

With a strong background in therapeutic antibodies, antibody drug conjugates (ADCs), and bi-functional compounds, he has successfully led cross-functional teams and been involved in numerous IND and BLA submissions.

Hans-Peter has a remarkable scientific track record with over 100 peer-reviewed publications, numerous patent filings, and a deep knowledge of preclinical and clinical genomics and companion diagnostics.

He has held key positions at renowned organizations like Pfizer, Seattle Genetics, and Genentech, and currently serves as the CSO and SVP at 3T Biosciences, where he oversees the development of pioneering TCR-based cancer therapies.

As a proven leader in the industry, Hans-Peter has excelled in building cross-functional teams, driving collaborations, and aligning corporate strategies to deliver impactful therapeutic platforms.

Hans-Peter Gerber
Add to my network

Location

South San Francisco, California, United States